Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZB001 SAD in Healthy Chinese Subjects
NCT05542303Phase 1Completed
- Sponsor
- Zenas BioPharma
- Start
- Oct 2022
- Primary completion
- Apr 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of veligrotug in thyroid eye disease (TED) (3 arms), sponsored by Zenas BioPharma. Primary endpoint: Number of participants with treatment-emergent adverse events at 4 weeks. Started Oct 2022; status: completed.
02
Drugs
veligrotug
03
Conditions
thyroid eye disease (TED)
Beyond the preview
Go deeper on NCT05542303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05542303.